NZ Lymphoma / Leukaemia Research Review Issue 36

In this Issue:

Leukaemia selection 
MRD improves prediction of outcomes in CLL with PR
Ibrutinib for relapsed/refractory del17p CLL
RUNX1 mutations in AML associated with distinct clinicopathological and genetic features
TP53 and decitabine in AML  and MDS
Rituximab in B-lineage acute lymphoblastic leukaemia
Lymphoma selection
Lenalidomide with R-bendamustine in elderly mantle-cell lymphoma
Risk model for CNS relapse in R-CHOP-treated DLBCL
Early event status informs outcomes in newly diagnosed FL
Brentuximab vedotin + AVD  with involved-site RT in unfavourable HL
Brentuximab vedotin for  relapsed/refractory HL

Please login below to download this issue (PDF)